Article citationsMore>>
Amadori, S., Suciu, S., Selleslag, D., Stasi, R., Alimena, G., Baila, L., Rizzoli, V., Borlenghi, E., Gaidano, G., Magro, D., Torelli, G., Muus, P., Venditti, A., Cacciola, E., Lauria, F., Vignetti, M. and de Witte, T. (2010) Randomized trial of two schedules of low-dose gemtuzumab ozogamicin as induction monotherapy for newly diagnosed acute myeloid leukaemia in older patients not considered candidates for intensive chemotherapy. A phase II study of the EORTC and GIMEMA leukaemia groups (AML-19). British Journal of Haematology, 149, 376-382.
doi:10.1111/j.1365-2141.2010.08095.x
has been cited by the following article:
-
TITLE:
Gemtuzumab ozogamicin in the treatment of adult acute myeloid leukemia
AUTHORS:
Hiroko Tsunemine, Takayuki Takahashi
KEYWORDS:
Gemtuzumab Ozogamicin; Acute Myeloid Leukemia; Acute Promyelocytic Leukemia; Monotherapy; Combination Chemotherapy; Sinusoidal Obstruction Syndrome; Veno-Occlusive Disease
JOURNAL NAME:
Health,
Vol.5 No.5A,
May
27,
2013
ABSTRACT:
Gemtuzumab ozogamicin (GO) is a humanized
anti-CD33 monoclonal antibody conjugated to a derivative
of an antitumor antibiotic, calicheamicin. GO was approved for the treatment
of relapsed acute myeloid leukemia (AML) in the United States (US) in 2000.
However, GO was withdrawn from the US
market in June 2010, because a large-scale clinical trial failed to show
additive or synergistic effects with conventional chemotherapy for newly
diagnosed AML. GO is currently available
only in Japan. However, several large clinical studies have demonstrated
beneficial effects of GO when added to chemotherapy for AML in recent years;
therefore, reconsideration of GO availability is gaining attention. Therefore,
the role and efficacy of GO as monotherapy or in combination therapy for de novo or relapsed AML should be
positively investigated.
Related Articles:
-
Hiroko Tsunemine, Takayuki Takahashi
-
N’guessan Boka Robert, Bamba El Hadji Sawaliho, Koffi Kouassi Alain
-
Ablé Anoh Valentin, N’Guessan Boka Robert, Bamba El Hadji Sawaliho
-
Bamba El Hadji Sawaliho, N’Guessan Boka Robert
-
Salah Mabrouk Khallaf, Elsayed Mostafa Ali, Ahmed M. Maklad, Mohamed Medhat Samir, Anwar Tawfik Amin, Muhammad Abbas El-Masry, Mona M. Sayed, Dalia Osama